New data reinforces improved and durable responses of Orencia in moderate-to-severe early rheumatoid arthritis patients with autoantibodies linked to more severe disease. – BMS
Bristol Myers Squibb announced results from the open-label switch period of Early AMPLE, a Phase IV exploratory biomarker study assessing the differences by which Orencia (abatacept) and another… read more.